[Eosinopenia in 2018]
H Gil1, B Bouldoires1, B Bailly1
1Service de médecine interne, CHU Jean-Minjoz, 25000 Besançon, France.
La Revue De Medecine Interne
|December 4, 2018
Summary
Eosinopenia, a long-standing biological test, aids in diagnosing bacterial infections and serves as a reliable mortality marker. Its diagnostic value is comparable to procalcitonin but at no extra cost.
Area of Science:
- Clinical Pathology
- Infectious Disease Diagnostics
- Biomarker Research
Background:
- Eosinopenia has been utilized since 1893 as a diagnostic indicator for bacterial infections.
- Its utility is well-documented in critical care, pulmonology, and pediatric settings.
- Previous studies highlight its significance in managing cerebrovascular diseases and post-coronary bypass patients.
Purpose of the Study:
- To evaluate the diagnostic and prognostic value of eosinopenia in bacterial infections.
- To assess the impact of the CIBLE score on enhancing eosinopenia's diagnostic performance.
- To determine the reliability of eosinopenia monitoring as a mortality predictor.
Main Methods:
- Review of existing literature and clinical data on eosinopenia.
- Analysis of diagnostic performance metrics in various clinical units.
- Evaluation of the CIBLE score's contribution to eosinopenia-based diagnosis.
- Assessment of eosinopenia trends in relation to patient mortality.
Main Results:
- Eosinopenia demonstrates significant diagnostic value for bacterial infections, comparable to procalcitonin.
- The CIBLE score enhances the diagnostic accuracy of eosinopenia in routine clinical practice.
- Monitoring eosinopenia levels provides a reliable indicator of patient mortality risk.
Conclusions:
- Eosinopenia is a cost-effective and valuable biomarker for diagnosing bacterial infections.
- The CIBLE score improves the clinical utility of eosinopenia.
- Eosinopenia monitoring is a significant prognostic tool for patient outcomes.
